ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Taken together, NAFLD patients had lower adiponectin levels, and adiponectin had protective effects on the pathogenesis of NAFLD by activating PPAR-α and AMPK signaling pathways through AdipoR1 and AdipoR2.